Dihexa vs Cerebrolysin — Which Peptide Wins for Brain & Memory?
Dihexa vs Cerebrolysin: Which Peptide Wins for Brain & Memory?
Reviewed by the CoreSup Research Team · Based on Washington State University pharmacology research, Cochrane meta-analyses of Cerebrolysin clinical trials, and PubMed-indexed literature · Updated March 2026
If you have moved beyond mainstream nootropics and are researching compounds with genuine neurobiological depth, Dihexa and Cerebrolysin will both appear on your list. They are the two most pharmacologically serious pro-cognitive compounds available outside of approved Alzheimer's medicines — and they are frequently compared by experienced neurohackers trying to decide where to invest.
The comparison is genuinely interesting because the two compounds share a broad goal (cognitive improvement, neuroprotection, potential Alzheimer's relevance) while approaching it through completely different mechanisms, using completely different administration routes, with completely different evidence bases. One is a precision-engineered synthetic peptidomimetic from an American university lab with potent but narrowly studied effects. The other is a biological extract from pig brain peptides with forty years of clinical trial history across thousands of patients.
This guide gives you the honest, evidence-based comparison you need to decide.
Quick Verdict: Cerebrolysin has a larger, more robust clinical evidence base — particularly for stroke and Alzheimer's. Dihexa has a more targeted mechanism (synaptogenesis via HGF/c-Met) and potentially greater potency per molecule, but lacks human trial data. For clinically-supported neuroprotection: Cerebrolysin. For maximum synaptogenic potential with acceptable uncertainty: Dihexa. For serious neurological conditions, always consult a physician.
Dihexa vs Cerebrolysin: Full Comparison
| Feature | Dihexa | Cerebrolysin |
|---|---|---|
| Origin | Synthetic peptidomimetic (WSU, USA) | Biological extract from porcine brain tissue |
| Primary mechanism | HGF/c-Met activation, synaptogenesis | Multiple neurotrophic factors: BDNF, NGF, CNTF, GDNF |
| Administration | Oral capsules or transdermal cream | Intramuscular or intravenous injection only |
| Bioavailability | High (oral and transdermal) | High (parenteral only — injectable) |
| Human clinical trials | None for Dihexa directly | Extensive (50+ trials, Cochrane-reviewed) |
| Approved uses | Research use only | Approved in 30+ countries for dementia, stroke, TBI |
| Evidence quality (human) | Not established | Moderate (Cochrane: some positive evidence with caveats) |
| In vitro potency | ~107× more potent than BDNF in synaptogenesis | Not comparably characterised |
| Cancer risk concern | Theoretical (HGF/c-Met pathway) | None documented |
| Cost (per cycle) | Moderate ($50–120 for 4 weeks oral) | Moderate–High ($60–200 for ampoules) |
| Ease of use | Easy (oral/transdermal) | Requires injections — less convenient |
| Stackable? | Yes — different mechanisms, often combined in advanced protocols | |
What Is Cerebrolysin?
Cerebrolysin is a biological preparation derived from enzymatically digested porcine (pig) brain tissue. The manufacturing process — developed by EVER Neuro Pharma in Austria — produces a highly purified solution containing approximately 25% low-molecular-weight peptides and amino acids, with 75% free amino acids. The active peptide fraction includes fragments of BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), CNTF (ciliary neurotrophic factor), GDNF (glial cell line-derived neurotrophic factor), and several other endogenous neuropeptides.
Unlike most synthetic nootropics, Cerebrolysin has been in clinical use since the 1970s and has accumulated a substantial body of human evidence. It is approved as a prescription medicine in over 30 countries — including Russia, Ukraine, China, South Korea, and much of Eastern Europe and Asia — for treatment of Alzheimer's disease, stroke, traumatic brain injury, and vascular dementia.
How They Work: Mechanism Deep-Dive
Dihexa: Targeted Synaptogenesis via HGF/c-Met
Dihexa works through a single, highly specific mechanism: activation of c-Met receptors by mimicking hepatocyte growth factor (HGF). This triggers synaptogenesis — the formation of new synaptic connections between neurons. The effect is structural: Dihexa potentially increases the number of functional synapses in the hippocampus and cortex, which is the physical basis for learning and memory storage.
The extraordinary in vitro potency (reported 10 million times greater than BDNF in synaptogenesis assays) reflects the molecule's efficiency at this specific task. But it does not modulate the broader neurotrophic environment the way Cerebrolysin does.
Cerebrolysin: Broad Neurotrophic Support
Cerebrolysin acts like a neurotrophic factor cocktail. By delivering fragments of BDNF, NGF, CNTF, and GDNF simultaneously, it supports a wide range of neuroprotective and restorative functions:
- BDNF fragments: Synaptic plasticity, neuronal survival, memory consolidation
- NGF fragments: Cholinergic neuron support (important in Alzheimer's), peripheral nerve integrity
- CNTF fragments: Motor neuron survival, protection against excitotoxicity
- GDNF fragments: Dopaminergic neuron support, protection of substantia nigra neurons (Parkinson's relevance)
This breadth is Cerebrolysin's key strength: it supports multiple neuronal populations simultaneously. The trade-off is less targeted potency on any single mechanism compared to Dihexa.
Benefits Comparison
Where Cerebrolysin Has the Edge
- Clinical validation: Human clinical trial evidence from 50+ studies, Cochrane-reviewed. No other nootropic peptide in this comparison has this level of evidence.
- Alzheimer's and stroke: Directly studied in these populations with meaningful clinical outcomes. Approved as medicine in many countries.
- Safety record: Four decades of clinical use. Known adverse event profile. No documented cancer risk.
- Broad neuroprotection: Simultaneous support for multiple neurotrophic pathways, not just one.
Where Dihexa Has the Edge
- Oral bioavailability: Unlike Cerebrolysin (injectable only), Dihexa works orally and transdermally. For UAE users who do not want to self-inject, this is a significant practical advantage.
- Synaptogenic potency: In the specific task of generating new synaptic connections, Dihexa is dramatically more potent per molecule than anything in Cerebrolysin.
- Target precision: Dihexa does one thing at extremely high potency. For users specifically seeking synaptogenesis (rather than broad neuroprotection), this precision is a feature.
- Novelty: The HGF/c-Met pathway represents a genuinely new mechanism not present in any approved Alzheimer's drug — giving Dihexa therapeutic potential that existing approved treatments do not cover.
When to Choose Each
- You want maximum synaptogenic support (new synapse formation)
- You cannot or will not use injectable compounds
- You want to explore a mechanism not covered by any existing approved drug
- You are willing to accept less human evidence in exchange for potentially greater potency
- You do not have a cancer history and understand the theoretical HGF risk
- You want the compound with the most robust human clinical evidence
- You have a specific neurological condition (post-stroke, Alzheimer's risk, TBI)
- Safety profile certainty is your top priority
- You are comfortable with injections (IM or IV)
- You want broad neurotrophic support across multiple pathways simultaneously
Dosage and Administration
| Parameter | Dihexa | Cerebrolysin |
|---|---|---|
| Route | Oral capsules or transdermal cream | IM or IV injection only |
| Standard dose | 10–30 mg/day | 5–30 mL/day (20% solution) |
| Cycle length | 2–4 weeks on, 2–4 weeks off | 10–28 day injection courses |
| Frequency | Once daily (morning) | Daily or 5 days on/2 off |
| Storage | Refrigerate; stable 6–12 months | Room temperature; stable 5 years (sealed) |
| Equipment needed | None (oral) or basic applicator (transdermal) | Syringes, needles, sterile technique |
Can You Stack Dihexa and Cerebrolysin?
Yes — this is considered an advanced cognitive peptide protocol and is used by some researchers specifically for age-related cognitive decline or post-neurological-injury recovery. The rationale is mechanistic complementarity: Dihexa drives synaptogenesis via the HGF/c-Met axis while Cerebrolysin provides broad neurotrophic support (BDNF, NGF, GDNF). These pathways do not overlap significantly and there is no theoretical antagonism.
Practical note: this stack is expensive, requires Cerebrolysin injections, and is more appropriate for individuals with specific neurological concerns than for general cognitive enhancement. Start each compound individually before combining. If adding Semax to this stack, consider the full Semax + Dihexa protocol guide.
Cost and Availability in the UAE
| Factor | Dihexa | Cerebrolysin |
|---|---|---|
| UAE availability | Available from research peptide suppliers | Available from some UAE pharmacies and research suppliers |
| Prescription required | No (research compound) | Technically prescription in many countries; varies |
| Approx cost (4-week cycle) | $50–120 (oral capsules) | $60–200 depending on dose and source |
| Convenience | High — oral daily dose | Low — daily injections required |
Buy Dihexa in the UAE
CoreSup stocks research-grade Dihexa in oral and transdermal forms — third-party tested with full certificates of analysis. Delivered across UAE in 2–3 business days.
Shop Dihexa at CoreSupFrequently Asked Questions
Which is more evidence-based — Dihexa or Cerebrolysin?
Cerebrolysin has far more human clinical evidence — 50+ randomised controlled trials reviewed in a 2020 Cochrane meta-analysis of over 33,000 patients. Dihexa has compelling animal model data and a well-characterised mechanism, but no human clinical trials have been completed. For evidence-based human use, Cerebrolysin is the stronger choice. Dihexa represents a higher-risk, higher-potential-reward option.
Is Cerebrolysin better than Dihexa for Alzheimer's prevention?
For the specific clinical indication of Alzheimer's disease, Cerebrolysin has direct human trial evidence and is approved as a medicine for this condition in multiple countries. Dihexa was designed for Alzheimer's research and has promising mechanism data, but lacks human evidence. For someone with a confirmed Alzheimer's diagnosis or family history, Cerebrolysin is the more defensible choice — ideally under physician guidance.
Why is Cerebrolysin injected and not oral?
The active peptide components of Cerebrolysin are proteins — they would be digested in the gastrointestinal tract before reaching systemic circulation if taken orally. Intramuscular or intravenous injection bypasses this. Dihexa, being a small lipophilic peptidomimetic, is specifically engineered to survive oral administration and cross biological barriers efficiently — which is a core part of its pharmacological design advantage.
Can beginners use Dihexa or Cerebrolysin?
Neither compound is ideal for peptide beginners. For those new to nootropic peptides, starting with Semax or Selank — which have decades of human clinical data, intranasal delivery, and excellent safety records — is the more appropriate first step. Both Dihexa and Cerebrolysin are better suited to researchers with experience who have specific reasons for their neurotrophic properties.
